Hassan M - Search Results

1

Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.

Felber M, Steward CG, Kentouche K, Fasth A, Wynn RF, Zeilhofer U, Haunerdinger V, Volkmer B, Prader S, Gruhn B, Ehl S, Lehmberg K, Müller D, Gennery AR, Albert MH, Hauck F, Rao K, Veys P, Hassan M, Lankester AC, Schmid JP, Hauri-Hohl MM, Güngör T. Felber M, et al. Among authors: hassan m. Blood Adv. 2020 May 12;4(9):1998-2010. doi: 10.1182/bloodadvances.2020001748. Blood Adv. 2020. PMID: 32384542 Free PMC article.

2

Busulfan bioavailability.

Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A, Starý J, Wallin I, Kållberg N. Hassan M, et al. Blood. 1994 Oct 1;84(7):2144-50. Blood. 1994. PMID: 7919328 Free article.

3

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.

Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syrůcková Z, van den Berg H, Sandström M, Karlsson M, Kumlien S, Vossen J. Hassan M, et al. Bone Marrow Transplant. 1996 Nov;18(5):843-50. Bone Marrow Transplant. 1996. PMID: 8932835

4

The role of busulfan in bone marrow transplantation.

Hassan M. Hassan M. Med Oncol. 1999 Sep;16(3):166-76. doi: 10.1007/BF02906128. Med Oncol. 1999. PMID: 10523796 Review.

5

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

Hassan M, Svensson JO, Nilsson C, Hentschke P, Al-Shurbaji A, Aschan J, Ljungman P, Ringdén O. Hassan M, et al. Ther Drug Monit. 2000 Aug;22(4):383-5. doi: 10.1097/00007691-200008000-00003. Ther Drug Monit. 2000. PMID: 10942175

6

Pharmacokinetics of liposomal busulphan in man.

Hassan Z, Ljungman P, Ringdén O, Winiarski J, Nilsson C, Aschan J, Whitley HR, Hassan M. Hassan Z, et al. Among authors: hassan m. Bone Marrow Transplant. 2001 Mar;27(5):479-85. doi: 10.1038/sj.bmt.1702823. Bone Marrow Transplant. 2001. PMID: 11313681 Clinical Trial.

7

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.

Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringdén O, Eber S, Seger R, Ljungman P. Hassan M, et al. Among authors: hassan z. Bone Marrow Transplant. 2002 Dec;30(12):833-41. doi: 10.1038/sj.bmt.1703739. Bone Marrow Transplant. 2002. PMID: 12476274 Clinical Trial.

8

N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

Sjöö F, Aschan J, Barkholt L, Hassan Z, Ringdén O, Hassan M. Sjöö F, et al. Among authors: hassan m, hassan z. Bone Marrow Transplant. 2003 Aug;32(4):349-54. doi: 10.1038/sj.bmt.1704143. Bone Marrow Transplant. 2003. PMID: 12900770

9

Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.

Mattsson J, Uzunel M, Remberger M, Hassan M. Mattsson J, et al. Among authors: hassan m. Bone Marrow Transplant. 2003 Sep;32(5):477-83. doi: 10.1038/sj.bmt.1704154. Bone Marrow Transplant. 2003. PMID: 12942093 Clinical Trial.

10

Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.

Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Winiarski J, Ringdén O, Hassan M. Mellgren K, et al. Among authors: hassan m. Bone Marrow Transplant. 2008 Apr;41(7):621-5. doi: 10.1038/sj.bmt.1705947. Epub 2007 Dec 17. Bone Marrow Transplant. 2008. PMID: 18084338 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,566 results

Search Page

Filters